Skip to main content
SpringerLink
Log in
Book cover

Parkinson's Disease pp 279–288Cite as

Encapsulated Cell Implants as a Novel Treatment for Parkinson's Disease

  • Protocol

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 62))

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive degeneration of the dopaminergic cells of the substantia nigra pars compacta (SNPc). Systemic levodopa therapy has proved to be an effective initial treatment for this disorder. However, resistance to this therapy inevitably develops with time, necessitating other approaches including surgery. Current experimental surgical treatments for this disorder include pallidal stimulation, pallidal lesion, subthalamic stimulation, and dopaminergic cell transplants. The current limitation of these approaches is that they all treat the symptoms but not the cause, that is, the progressive degeneration of the SNPc goes unabated.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Hoffer, B. J., Hoffman, A., Bowenkamp, K., Huettl, P., Hudson, J., Martin, D., Lin, L. H., and Gerhardt, G. A. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107–111.

    Article  CAS  PubMed  Google Scholar 

  2. Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., and Hefti, F. (1995) Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 373, 339–341.

    Article  CAS  PubMed  Google Scholar 

  3. Bowenkamp, K. E., Hoffman, A. F., Gerhardt, G. A., Henry, M. A., Biddle, P. T., Hoffer, B. J., and Granholm, A. C. (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355, 479–489.

    Article  CAS  PubMed  Google Scholar 

  4. Kearns, C. M., and Gash, D. M. (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104–111.

    Article  CAS  PubMed  Google Scholar 

  5. Sauer, H., Rosenblad, C., and Björklund, A. (1995) GDNF but not TGF-β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine-lesion. Proc. Natl. Acad. Sci. USA 92, 8935–8939.

    Article  CAS  PubMed  Google Scholar 

  6. Tomac, A., Lindqvist, E., Lin, L. H., ögren, S. O., Young, D., Hoffer, B. J., and Olson, L. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335–339.

    Article  CAS  PubMed  Google Scholar 

  7. Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., and Gerhardt, G. A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252–255.

    Article  CAS  PubMed  Google Scholar 

  8. Tseng, J. L., Baetge, E. E., Zurn, A. D., and Aebischer, P. (1997) GDNF reduces drug-induced rotational behavior following medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17, 325–333.

    CAS  PubMed  Google Scholar 

  9. Tseng, J. L., Bruhn, S. L., Zurn, A. D., and Aebischer, P. (1998) Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport 9, 1817–1822.

    Article  CAS  PubMed  Google Scholar 

  10. Freese, A., Neve, R., and Geller, A. I. (1990) HSV-1 vector mediated neuronal gene delivery: strategies for neuroscience and neurology. Biochem. Pharm. 40, 2189–2199.

    Article  CAS  PubMed  Google Scholar 

  11. Ugolini, G., Kuypers, H. G., and Strick, P. L. (1989) Transneuronal transfer of herpes virus from peripheral nerves to cortex and brainstem. Science 243, 89–9

    Article  CAS  PubMed  Google Scholar 

  12. Freese, A., Stern, M., Kaplitt, M. G., O’Connor, W. M., Abbey, M. V., O’Connor, M. J., and During, M. J. (1996) Prospects for gene therapy in Parkinson’s disease. Movement Disord. 11, 469–488.

    Article  CAS  PubMed  Google Scholar 

  13. Baringer, J. R. and Sworeland, P. (1973) Recovery of herpes-simplex virus from human trigeminal ganglions. N. Engl. J. Med. 228, 9593–9596.

    Google Scholar 

  14. Cook, M. L., Bastone, U. B., and Stevens, J. G. (1974) Evidence that neurons harbor latent herpes simplex virus. Infect. Immun. 9, 946–951.

    CAS  PubMed  Google Scholar 

  15. Spaete, R. R. and Frenkel, N. (1982) The herpes simplex virus amplicon: a new eucaryotic defective virus cloning-amplifying vector. Cell 30, 295–304.

    Article  CAS  PubMed  Google Scholar 

  16. Palella, T. D., Hidaka, Y., Silverman, L. J., Levine, M., Glorioso, J., and Kelley, W. N. (1989) Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene 80, 137–144.

    Article  CAS  PubMed  Google Scholar 

  17. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–856.

    Article  CAS  PubMed  Google Scholar 

  18. During, M. J., Naegele, J. R., O’Malley, K. L., and Geller, A. I. (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399–1403.

    Article  CAS  PubMed  Google Scholar 

  19. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O’Malley, K. L., and During, M. J. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. 8, 148–154.

    Article  CAS  PubMed  Google Scholar 

  20. Akli, S., Caillaud, C., Vigne, E., Stratford-Perricaudet, L. D., Poenaru, L., Perricaudet, M., Kahn, A., and Peschanski, M. R. (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet. 3, 224–234.

    Article  CAS  PubMed  Google Scholar 

  21. Davidson, B. L., Allen, E. D., Kozarsky, K. F., Wilson, J. M., and Roessler, B. J. (1993) A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet. 3, 219–223.

    Article  CAS  PubMed  Google Scholar 

  22. Le Gal La Salle, G., Robert, J. J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L. D., Perricaudet, M., and Mallet, J. (1993) An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259, 988–990.

    Article  CAS  PubMed  Google Scholar 

  23. Neve, R. L. (1993) Adenovirus vectors enter the brain. Trends Neurosci. 16, 251–253.

    Article  CAS  PubMed  Google Scholar 

  24. Mallet, J., Le Gal La Salle, G., Robert, J. J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L. D., and Perriaudet, M. (1994) Adenovirus mediated gene transfer to the central nervous system. Gene Ther. 1 Suppl 1, S52.

    PubMed  Google Scholar 

  25. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996) In vivo gene delivery and stable transduction of nondi-viding cells by a lentiviral vector. Science 272, 263–267.

    Article  CAS  PubMed  Google Scholar 

  26. Suhr, S. T., and Gage, F. H. (1993) Gene therapy for neurologic disease. Arch. Neurol. 30, 1252–1268.

    Google Scholar 

  27. Karpati, G., Lochmüller, H., Nalbantoglu, J., and Durham, H. (1996) The principles of gene therapy for the nervous system. Trends Neurosci. 19, 49–54.

    Article  CAS  PubMed  Google Scholar 

  28. Horellou, P., Brundin, P., Kalen, P., Mallet, J., and Björklund, A. (1990) In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 5, 393–402.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher, L. J., Jinnah, H. A., Kale, L. C., Higgins, G. A., and Gage, F. H. (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371–380.

    Article  CAS  PubMed  Google Scholar 

  30. Kang, U. J., Fisher, L. J., Joh, T. H., O’Malley, K. L., and Gage, F. H. (1993) Regulation of dopamine production by genetically modified primary fibroblasts. J. Neurosci. 13, 5203–5211.

    CAS  PubMed  Google Scholar 

  31. Levivier, M., Przedborski, S., Bencsics, C., and Kang, U. J. (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J. Neurosci. 15, 7810–7820.

    CAS  PubMed  Google Scholar 

  32. Uchida, K., Ishii, A., Kaneda, N., Toya, S., Nagatsu, T., and Kohsaka, S. (1990) Tetrahydrobiopterin-dependent production of L-dopa in NRK fibroblasts trans-fected with tyrosine hydroxylase cDNA: future use for intracerebral grafting. Neurosci. Lett. 109, 282–286.

    Article  CAS  PubMed  Google Scholar 

  33. Uchida, K., Tsuzaki, N., Nagatsu, T., and Kohsaka, S. (1992) Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA. Dev. Neurosci. 14, 173–180.

    Article  CAS  PubMed  Google Scholar 

  34. Kawaja, M. D., Fagan, A. M., Firestein, B. L., and Gage, F. H. (1991) Intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum: an assessment of graft size and ultrastructure. J. Comp. Neurol. 307, 695–706.

    Article  CAS  PubMed  Google Scholar 

  35. Jiao, S., and Wolff, J. A. (1992) Long-term survival of autologous muscle grafts in rat brain. Neurosci. Lett. 137, 207–210.

    Article  CAS  PubMed  Google Scholar 

  36. O’Malley, K., and Geller, A. I. (1992) Gene therapy in neurology: potential application to Parkinson’s disease, in Neurological Disorders: Novel Experimental and Therapeutic Strategies (Vecsei, L., Freese, A., Swartz, K. J., and Beal, M. F., eds.), Ellis Horwood, West Sussex, England, pp. 223–248.

    Google Scholar 

  37. Lindner, M. D., Plone, M. A., Frydel, B., Kaplan, F., Krueger, M., Bell, W. J., et al. (1996) Intraventricular encapsulated CAC cells: viable for at least 500 days in vivo without detectable host immune sensitization or adverse effects on behavioral/cognitive function. Soc. Neurosci. Abstr. 22, 306.3.

    Google Scholar 

  38. Aebischer, P., Tresco, P. A., Winn, S. R., Greene, L. A., and Jaeger, C. B. (1991) Long-term cross-species brain transplantation of a polymer-encapsulated dopam-ine-secreting cell line. Exp. Neurol. 111, 269–275.

    Article  CAS  PubMed  Google Scholar 

  39. Aebischer, P., Wahlberg, L., Tresco, P. A., and Winn, S. R. (1991) Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer solution. Biomaterials 12, 50–56.

    Article  CAS  PubMed  Google Scholar 

  40. Aebischer, P., Pochon, N. A.-M., Heyd, B., Déglon, N., Joseph, J.-M., Zurn, A. D., et al. (1996) Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum. Gene Ther. 7, 851–860.

    Article  CAS  PubMed  Google Scholar 

  41. Aebischer, P., Schluep, M., Déglon, N., Joseph, J-M., Hirt, L., Heyd, B., Goddard, M. B., Hammang, J. P., Zurn, A. D., Kato, A. C., Regli, F., and Baetge, E. E. (1996) Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med. 2, 696–699.

    Article  CAS  PubMed  Google Scholar 

  42. ALS CNTF Treatment Study Group (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 46, 1244–1249.

    Google Scholar 

  43. Oztas, B. and Kaya, M. (1994) The effect of profound hypothermia on blood-brain barrier permeability during pentylenetetrazol-induced seizures. Epilepsy Res. 19, 221–227.

    Article  CAS  PubMed  Google Scholar 

  44. Hussain, S. T. and Roots, B. I. (1994) Effect of essential fatty acid deficiency and immunopathological stresses on blood brain barrier (B-BB) in Lewis rats: a biochemical study. Biochem. Soc. Trans. 22, 338S.

    CAS  PubMed  Google Scholar 

  45. Ijima, T., Kubota, Y., Kuroiwa, T., and Sankawa, H. (1994) Blood-brain barrier opening following transient reflex sympathetic hypertension. Acta Neurochir. Suppl. 60, 142–144.

    Google Scholar 

  46. Tang, J. P., Xu, Z. Q., Douglas, F. L., Rakhit, A., and Melethil, S. (1993) Increased blood-brain barrier permeability of amino acids in chronic hypertension. Life Sci. 53, 417–420.

    Article  Google Scholar 

  47. Wijsman, J. A. and Shivers, R. R. (1993) Heat stress affects blood-brain barrier permeability to horseradish peroxidase in mice. Acta Neuropathol. 86, 49–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Research and Gene Therapy Center, Lausanne University Medical School, Lausanne, Switzerland

    Jack L. Tseng & Patrick Aebischer

Authors
  1. Jack L. Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Aebischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD

    M. Maral Mouradian MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc.

About this protocol

Cite this protocol

Tseng, J.L., Aebischer, P. (2001). Encapsulated Cell Implants as a Novel Treatment for Parkinson's Disease. In: Maral Mouradian, M. (eds) Parkinson's Disease. Methods in Molecular Medicine™, vol 62. Humana Press. https://doi.org/10.1385/1-59259-142-6:279

Download citation

  • DOI: https://doi.org/10.1385/1-59259-142-6:279

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-761-8

  • Online ISBN: 978-1-59259-142-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation